Safety Findings Appear Encouraging for REGN5458 in Relapsed/Refractory Myeloma
January 14th 2021Deepu Madduri, MD, discusses the safety findings from a first-in-human phase 1 study of REGN5458, a BCMA x CD3 bispecific monoclonal antibody, as treatment of patients with relapsed/refractory multiple myeloma.